相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study*
L. Gianni et al.
ANNALS OF ONCOLOGY (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Paolo Tarantino et al.
NPJ BREAST CANCER (2022)
Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)
B. Conte et al.
ANNALS OF ONCOLOGY (2022)
Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities
Ingrid Boere et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2022)
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
Maroun Bou Zerdan et al.
CANCERS (2022)
Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis
Neha Pathak et al.
BREAST (2022)
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC
Meghan J. O'Melia et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tess A. O’Meara et al.
Oncotarget (2021)
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Francesco Schettini et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S. Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
M. Garutti et al.
ESMO OPEN (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai et al.
CANCER CELL (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Francesco Schettini et al.
FRONTIERS IN ONCOLOGY (2021)
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
Enrica Teresa Tanda et al.
FRONTIERS IN ONCOLOGY (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
Giovanna Garufi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
It Is Time to Talk About Fertility and Immunotherapy
Narjust Duma et al.
ONCOLOGIST (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T. Karn et al.
ANNALS OF ONCOLOGY (2020)
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Mauricio A. Medina et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
Milan Radovich et al.
JAMA ONCOLOGY (2020)
Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2020)
Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients
Nicolas Gonzalo Nunez et al.
NATURE COMMUNICATIONS (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer
Yi-Yu Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype
Soumaya Allouch et al.
FRONTIERS IN ONCOLOGY (2020)
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
Xuefeng Bai et al.
ENDOCRINE (2020)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Isolated Hypogonadotropic Hypogonadism Secondary to Anti-Programmed Death Ligand 1 Inhibitor
Amy Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Counseling young women with early breast cancer on fertility preservation
M. E. (elena) ter Welle-Butalid et al.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor characteristics and prognosis in women with pregnancy-associated breast cancer
Anna L. V. Johansson et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer
E Obeid et al.
CANCER RESEARCH (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Angela Santonja et al.
Oncotarget (2018)
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.
Charles E. Geyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2018)
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
Bastien Nguyen et al.
NPJ BREAST CANCER (2018)
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
Xiaoxian Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2017)
The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Ting Wang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Circulating-tumor DNA as an early detection and diagnostic tool
Timothy M. Butler et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
Cancer and fertility preservation: international recommendations from an expert meeting
Matteo Lambertini et al.
BMC MEDICINE (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin et al.
ONCOLOGIST (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature
Suvradeep Mitra et al.
CYTOJOURNAL (2016)
Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer
Patricia Cortazar et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Clinical implications of molecular heterogeneity in triple negative breast cancer
Brian D. Lehmann et al.
BREAST (2015)
Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer
Philip C. Schouten et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
Alexander M. Lesokhin et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR plus or Quadruple Negative Disease
Valerie N. Barton et al.
HORMONES & CANCER (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Ultrasound for fetal assessment in early pregnancy
Melissa Whitworth et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial
Helena M. Earl et al.
LANCET ONCOLOGY (2014)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Following up tumor-specific regulatory T cells in cancer patients
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2013)
Triple-negative breast cancer in the older population
P. Boyle
ANNALS OF ONCOLOGY (2012)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L. Malorni et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
Cheng Fan et al.
BMC MEDICAL GENOMICS (2011)
Higher Population-Based Incidence Rates of Triple-Negative Breast Cancer Among Young African-American Women Implications for Breast Cancer Screening Recommendations
Kathryn C. Amirikia et al.
CANCER (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
Jennifer K. Litton et al.
ONCOLOGIST (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Second Cell Death Network symposium: the vital cell death
T. Panaretakis et al.
CELL DEATH AND DIFFERENTIATION (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
Bruce G. Haffty et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy
WT Yang et al.
RADIOLOGY (2006)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Breast carcinoma in pregnant women - Assessment of clinicopathologic and immunohistochemical features
LP Middleton et al.
CANCER (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
